{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:12:17Z","timestamp":1787857937006,"version":"build-2784847793"},"reference-count":51,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo (S\u00e3o Paulo Research Foundation)","award":["2020\/03342-3"],"award-info":[{"award-number":["2020\/03342-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The diagnosis of cystic fibrosis has improved in the last few years due to greater access to diagnostic tools and the evolution of molecular biology; the knowledge obtained has contributed to the understanding of its death profile. In this context, an epidemiological study was developed focusing on deaths from cystic fibrosis in Brazil from 1996 to 2019. The data were collected from the Data-SUS (Unified National Health System Information Technology Department from Brazil). The epidemiological analysis included patients\u2019 age groups, racial groups, and sex. In our data, between 1996 and 2019, \u03a33050 deaths were recorded, totaling a \u2245330% increase in the number of deaths resulting from cystic fibrosis. This fact might be related to a better diagnosis of the disease, mainly in patients from racial groups that are not commonly associated with cystic fibrosis, such as Black individuals, Hispanic or Latino (mixed individuals\/Pardos) individuals, and American Indians (Indigenous peoples from Brazil). Regarding of race, the \u03a3 of deaths was: nine (0.3%) in the American Indian group, 12 (0.4%) in the Asian group, 99 (3.6%) in the Black or African American group, 787 (28.6%) in the Hispanic or Latino group, and 1843 (67.0%) in the White group. The White group showed the highest prevalence of deaths, and the increase in mortality was \u2245150 times in this group, while, in the Hispanic or Latino group, it was \u224575 times. Regarding sex, the numbers and percentage of deaths of both male (N = 1492; 48.9%) and female (N = 1557; 51.1%) patients were seen to be relatively close. As for age groups, the &gt;60-year-old group presented the most significant results, with an increase of \u224560 times in the registered deaths. In conclusion, in Brazil, despite the number of deaths from cystic fibrosis being prevalent in the White group, it increased in all racial groups (Hispanic or Latino, Black or African American, American Indian, or Asian individuals) and was associated with older age.<\/jats:p>","DOI":"10.3390\/diagnostics13040763","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T03:27:41Z","timestamp":1676604461000},"page":"763","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cystic Fibrosis: A Descriptive Analysis of Deaths in a Two-Decade Period in Brazil According to Age, Race, and Sex"],"prefix":"10.3390","volume":"13","author":[{"given":"Luan Victor Frota","family":"de Azevedo","sequence":"first","affiliation":[{"name":"Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Laboratory of Human and Medical Genetics, Postgraduate Program in Health Science, S\u00e3o Francisco University, Bragan\u00e7a Paulista 12916-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Cristine Ribeiro Medeiros","family":"Cruz","sequence":"additional","affiliation":[{"name":"Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Laboratory of Human and Medical Genetics, Postgraduate Program in Health Science, S\u00e3o Francisco University, Bragan\u00e7a Paulista 12916-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-756X","authenticated-orcid":false,"given":"J\u00e9ssica Paula","family":"Martins","sequence":"additional","affiliation":[{"name":"Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Laboratory of Human and Medical Genetics, Postgraduate Program in Health Science, S\u00e3o Francisco University, Bragan\u00e7a Paulista 12916-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-4234","authenticated-orcid":false,"given":"Fernando Augusto Lima","family":"Marson","sequence":"additional","affiliation":[{"name":"Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, Laboratory of Human and Medical Genetics, Postgraduate Program in Health Science, S\u00e3o Francisco University, Bragan\u00e7a Paulista 12916-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist\u2019s perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcf.2020.08.007","article-title":"Extensive CFTR sequencing through NGS in Brazilian individuals with cystic fibrosis: Unravelling regional discrepancies in the country","volume":"20","author":"Athanazio","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCP.0000000000000520","article-title":"Cystic fibrosis survival: The changing epidemiology","volume":"24","author":"Corriveau","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2022.06.006","article-title":"Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries","volume":"85","author":"Gabbi","year":"2022","journal-title":"J. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Scotet, V., L\u2019Hostis, C., and F\u00e9rec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.","DOI":"10.3390\/genes11060589"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Shum, B.O.V., Bennett, G., Navilebasappa, A., and Kumar, R.K. (2021). Racially equitable diagnosis of cystic fibrosis using next-generation DNA sequencing: A case report. BMC Pediatr., 21.","DOI":"10.1186\/s12887-021-02609-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9812074","DOI":"10.1155\/2021\/9812074","article-title":"Next-Generation Sequencing for Molecular Diagnosis of Cystic Fibrosis in a Brazilian Cohort","volume":"2021","author":"Cambraia","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/ppul.24434","article-title":"The demographics of adverse outcomes in cystic fibrosis","volume":"54","author":"McGarry","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_10","first-page":"e13526","article-title":"A Rare Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation Associated with Typical Cystic Fibrosis in an Arab Child","volume":"13","author":"Mathew","year":"2021","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-022-02279-9","article-title":"Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians","volume":"17","author":"Ni","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/resp.12656","article-title":"Epidemiology and genetics of cystic fibrosis in Asia: In preparation for the next-generation treatments","volume":"20","author":"Singh","year":"2015","journal-title":"Respirology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jcf.2016.05.007","article-title":"Cystic fibrosis in Latin America-Improving the awareness","volume":"15","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpeds.2016.03.046","article-title":"Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis","volume":"175","author":"Sontag","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fphar.2017.00390","article-title":"Personalized or Precision Medicine? The Example of Cystic Fibrosis","volume":"8","author":"Marson","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_17","first-page":"73","article-title":"Rate of pulmonary function decline in South African children with cystic fibrosis","volume":"3","author":"Morrow","year":"2009","journal-title":"SAJCH"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1590\/s1806-37562017000000065","article-title":"Brazilian guidelines for the diagnosis and treatment of cystic fibrosis","volume":"43","author":"Athanazio","year":"2017","journal-title":"J. Bras. Pneumol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e20190308","DOI":"10.36416\/1806-3756\/e20190308","article-title":"Cost of precision medicine at a referral center for cystic fibrosis","volume":"46","author":"Marson","year":"2020","journal-title":"J. Bras. Pneumol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1038\/s41598-019-45017-1","article-title":"Severe pulmonary disease in an adult primary ciliary dyskinesia population in Brazil","volume":"9","author":"Olm","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Toro, M.D.C., Ribeiro, J.D., Marson, F.A.L., Ortiz, \u00c9., Toro, A.A.D.C., Bertuzzo, C.S., Jones, M.H., and Sakano, E. (2022). Challenges in Diagnosing Primary Ciliary Dyskinesia in a Brazilian Tertiary Hospital. Genes, 13.","DOI":"10.3390\/genes13071252"},{"key":"ref_23","unstructured":"(2022, December 10). Unified National Health System Information Technology Department, DATA-SUS, Available online: http:\/\/www2.datasus.gov.br\/DATASUS."},{"key":"ref_24","unstructured":"(2023, January 12). Cor ou ra\u00e7a|Educa|Jovens\u2014IBGE, Available online: https:\/\/educa.ibge.gov.br\/jovens\/conheca-o-brasil\/populacao\/18319-cor-ou-raca.html."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"05027","DOI":"10.7189\/jogh.12.05027","article-title":"Characterization of demographic data, clinical signs, comorbidities, and outcomes according to the race in hospitalized individuals with COVID-19 in Brazil: An observational study","volume":"12","author":"Sansone","year":"2022","journal-title":"J. Glob. Health"},{"key":"ref_26","unstructured":"(2023, January 12). The Difference between Race and Ethnicity\u2014Merriam-Webster Dictionary. Available online: https:\/\/www.merriam-webster.com\/words-at-play\/difference-between-race-and-ethnicity."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Palamim, C.V.C., Boschiero, M.N., Valencise, F.E., and Marson, F.A.L. (2022). Human Development Index Is Associated with COVID-19 Case Fatality Rate in Brazil: An Ecological Study. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19095306"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/ppul.24726","article-title":"Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007-2016","volume":"55","author":"Vandenbroucke","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dagenais, R.V.E., Su, V.C.H., and Quon, B.S. (2020). Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010023"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of ELX\/TEZ\/IVA in Children 6 Through 11 Years of Age with CF and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1590\/s1806-37562016000000076","article-title":"Sweat test and cystic fibrosis: Overview of test performance at public and private centers in the state of S\u00e3o Paulo, Brazil","volume":"43","author":"Servidoni","year":"2017","journal-title":"J. Bras. Pneumol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201606-481FR","article-title":"Cystic Fibrosis in the African Diaspora","volume":"14","author":"Stewart","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1111\/jcmm.17605","article-title":"Screening by high-throughput sequencing for pathogenic variants in cystic fibrosis: Benefit of introducing personalized therapies","volume":"26","author":"Maia","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1038\/s41598-019-42404-6","article-title":"Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools","volume":"9","author":"Pereira","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2214\/AJR.16.17462","article-title":"Multisystem Imaging Findings of Cystic Fibrosis in Adults: Recognizing Typical and Atypical Patterns of Disease","volume":"209","author":"Averill","year":"2017","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pulmoe.2021.09.004","article-title":"Impact of CFTR large deletions and insertions on the clinical and laboratory severity of cystic fibrosis: A serial case report","volume":"28","author":"Pereira","year":"2022","journal-title":"Pulmonology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jmoldx.2015.07.005","article-title":"The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing","volume":"18","author":"Schrijver","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MCP.0000000000000479","article-title":"Disease-modifying genetic factors in cystic fibrosis","volume":"24","author":"Marson","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ppul.24005","article-title":"Interaction among variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1, and SLC9A3) and CFTR mutations with clinical markers of cystic fibrosis","volume":"53","author":"Pereira","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbadis.2019.01.029","article-title":"Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del\/F508del Cystic Fibrosis patients","volume":"1865","author":"Kmit","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_45","first-page":"41","article-title":"Cystic fibrosis carrier frequencies in populations of African origin","volume":"36","author":"Padoa","year":"1999","journal-title":"J. Med. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.lpm.2017.04.010","article-title":"The diagnosis of cystic fibrosis","volume":"46","author":"Vermeulen","year":"2017","journal-title":"Presse Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/resp.12702","article-title":"Increasing awareness of sex differences in airway diseases","volume":"21","author":"Raghavan","year":"2016","journal-title":"Respirology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ccm.2022.06.002","article-title":"Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations","volume":"43","author":"McBennett","year":"2022","journal-title":"Clin. Chest Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.mcna.2022.07.005","article-title":"Cystic Fibrosis: Highly Effective Targeted Therapeutics and the Impact on Sex and Racial Disparities","volume":"106","author":"Montemayor","year":"2022","journal-title":"Med. Clin. N. Am."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"23743735221112629","DOI":"10.1177\/23743735221112629","article-title":"Evaluating Differences in the Disease Experiences of Minority Adults with Cystic Fibrosis","volume":"9","author":"Hutchins","year":"2022","journal-title":"J. Patient Exp."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.gim.2022.06.009","article-title":"CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis","volume":"24","author":"Vaidyanathan","year":"2022","journal-title":"Genet. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/4\/763\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:39:19Z","timestamp":1760121559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/4\/763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["diagnostics13040763"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13040763","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}